Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats

dc.contributor.authorDeCarlo, Arthur A.
dc.contributor.authorHammes, Nathan
dc.contributor.authorJohnson, Philip L.
dc.contributor.authorShekhar, Anantha
dc.contributor.authorSamuels, Brian C.
dc.contributor.departmentOphthalmology, School of Medicineen_US
dc.date.accessioned2023-05-24T11:54:30Z
dc.date.available2023-05-24T11:54:30Z
dc.date.issued2022
dc.description.abstractPurpose: Intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma progression. Our previous discovery that stimulation of nuclei within the hypothalamus can modulate IOP, intracranial pressure (ICP), and translaminar pressure difference (TLPD) fluctuations led us to investigate this pathway further. Our purpose was to determine the role of orexin neurons, primarily located in the dorsomedial hypothalamus (DMH) and perifornical (PeF) regions of the hypothalamus, in modulating these pressures. Methods: Sprague Dawley rats were pretreated systemically with a dual orexin receptor antagonist (DORA-12) at 30 mg/Kg (n = 8), 10 mg/Kg (n = 8), or vehicle control (n = 8). The IOP, ICP, heart rate (HR), and mean arterial pressure (MAP) were recorded prior to and following excitation of the DMH/PeF using microinjection of the gamma-aminobutyric acid (GABA)A receptor antagonist bicuculline methiodide (BMI). Results: Administration of the DORA at 30 mg/Kg significantly attenuated peak IOP by 5.2 ± 3.6 mm Hg (P = 0.007). During the peak response period (8-40 minutes), the area under the curve (AUC) for the 30 mg/Kg DORA cohort was significantly lower than the control cohort during the same period (P = 0.04). IOP responses for peak AUC versus DORA dose, from 0 to 30 mg/Kg, were linear (R2 = 0.18, P = 0.04). The ICP responses during the peak response period (4-16 minutes) versus DORA dose were also linear (R2 = 0.24, P = 0.014). Pretreatment with DORA significantly decreased AUC for the TLPD following stimulation of the DMH/PeF (10 mg/kg, P = 0.045 and 30 mg/kg, P = 0.015). Conclusions: DORAs have the potential to attenuate asynchronous changes in IOP and in ICP and to lessen the extent of TLPDs that may result from central nervous system (CNS) activation.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationDeCarlo AA, Hammes N, Johnson PL, Shekhar A, Samuels BC. Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats. Invest Ophthalmol Vis Sci. 2022;63(3):1. doi:10.1167/iovs.63.3.1en_US
dc.identifier.urihttps://hdl.handle.net/1805/33207
dc.language.isoen_USen_US
dc.publisherAssociation for Research in Vision and Ophthalmologyen_US
dc.relation.isversionof10.1167/iovs.63.3.1en_US
dc.relation.journalInvestigative Ophthalmology & Visual Scienceen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourcePMCen_US
dc.subjectGlaucomaen_US
dc.subjectHypothalamusen_US
dc.subjectOrexinen_US
dc.subjectIntraocular pressureen_US
dc.titleDual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Ratsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
iovs-63-3-1.pdf
Size:
886.21 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: